Amgen (AMGN) announced that the FDA has approved a new monthly dosing option for its cholesterol fighter Repatha (evolocumab), the first for a PCSK9 inhibitor. Patients can now self-administer a single subcutaneous dose of 420 mg of evolocumab using the hands-free Pushtronex device (on-body infusor with prefilled cartridge). The original dosing regimen, which remains in place, is 140 mg every two weeks.